A5014325215- Inflammatory Bowel Disease
- Microscopic Colitis
- Biosimilars and Bioanalytical Methods
- Diverticular Disease and Complications
- Anorectal Disease Treatments and Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Liver Diseases and Immunity
- Eosinophilic Esophagitis
- Helicobacter pylori-related gastroenterology studies
- Autoimmune and Inflammatory Disorders
- Liver Disease Diagnosis and Treatment
- Thallium and Germanium Studies
- Neuropeptides and Animal Physiology
- Renal Diseases and Glomerulopathies
- Celiac Disease Research and Management
- Colorectal and Anal Carcinomas
- IL-33, ST2, and ILC Pathways
- Diet, Metabolism, and Disease
- Gastric Cancer Management and Outcomes
- Gastrointestinal motility and disorders
- Tuberculosis Research and Epidemiology
- Biochemical Analysis and Sensing Techniques
- Mercury impact and mitigation studies
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Genetic factors in colorectal cancer
Copenhagen University Hospital
2018-2025
Amager Hospital
2023-2025
Hvidovre Hospital
2018-2024
University of Copenhagen
2015-2021
Novo Nordisk Foundation
2015
New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing worldwide, approximately 0.2% the European population suffer from IBD at present time. Medical therapy disease management have evolved significantly in recent decades, with an emphasis on tight objective monitoring progression a treat-to-target approach Europe also aiming to prevent early damage disability. Surgery rate declined over time Europe, 10-30% CD 5-10% UC patients requiring...
Perianal Crohn's disease [CD] places a considerable burden on patients' quality of life and is complex to treat. Despite its impact high frequency, few studies have investigated the incidence course perianal CD. The aim this study was assess CD in adult patients throughout 19-year period.The cohort comprised all individuals aged 18 years or older who were diagnosed with Denmark between January 1, 1997, December 31, 2015, according National Patient Registry [NPR].A total 1812 [19%] out 9739...
Summary Background Therapeutic management of inflammatory bowel diseases (IBD) is rapidly evolving, with an expanding armoury biological drugs at our disposal. However, real‐world findings about treatment persistence and the impact biologicals on surgery remain inconsistent. Aims This study aimed to investigate trends in use rates a nationwide cohort biological‐naïve IBD patients. Methods Patients who initiated between 2011 2018 were identified Danish National Patient Registry. Data...
In the stomach, somatostatin (SST) acts as a general paracrine negative regulator of exocrine secretion gastric acid and pepsinogen endocrine gastrin, ghrelin, histamine. Using reporter mice expressing red fluorescent protein (RFP) under control SST promotor, we have characterized G protein-coupled receptors expressed in Sst-RFP-positive cells probed their effects on primary cell cultures. Surprisingly, besides SST, amylin PYY were also highly enriched cells. Several found to regulate and/or...
Perianal complications in patients with Crohn's disease are common and have a negative impact on the patients' quality of life. Data about long-term course perianal era biological treatment limited. In this population-based cohort study, we sought to investigate occurrence, clinical risk factors, disease. A total 213 were included prospective inception cohort. retrieved from medical records national health administrative databases. was defined as fistula and/or abscess. Associations between...
Incidence rates of inflammatory bowel disease [IBD] reported from developed countries are rising, with some levelling out. The aim this study was to assess the burden IBD by estimating incidence and prevalence across age groups projecting these 2030 in a high-incidence country.Using an algorithm [incorporating ICD codes, medications histopathology], patients [n = 69 862] diagnosed Crohn's [CD] or ulcerative colitis [UC] between 1980 2017 were identified Danish National Patient Registry...
Abstract Background Musculoskeletal (MSK) involvement in IBD patients contributes to poorer outcomes and reduced quality of life (QoL). Recognising MSK is important before initiating biologics, as their effects can differ between the gut, peripheral joints spine. We aimed describe prevalence distribution axial symptoms clinical findings starting biological treatment. Methods Bio-naïve were consecutively recruited. assessed using questionnaires a structured interview. A rheumatologist...
Tofacitinib (TFB) appears to be effective in the treatment of ulcerative colitis (UC); however, available real-world studies are limited by cohort size. TFB could an option acute severe (ASUC). We aimed investigate efficacy and safety moderate-to-severe ASUC. This retrospective, international study enrolling UC patients with ≥6-week follow-up period was conducted from February 1 July 31, 2022. Indications were categorized as ASUC chronic activity (CA). Baseline demographic clinical data...
Abstract Background MR elastography can determine organ‐related stiffness, which reflects the degree of fibrosis. Liver stiffness increases in cirrhosis, and further post‐prandially due to increased portal blood in‐flow. Non‐selective beta‐blockers (NSBB) reduce venous inflow, but their effect on liver spleen are disputed. Aims To assess whether or severity treatment with NSBB changes predict pressure. Methods Fifty‐two patients cirrhosis underwent vein catheterization two‐dimensional (2D)...
Summary Background Despite the increasing use of biologics in patients with inflammatory bowel disease (IBD), real‐world data about outcomes era remain inconclusive. Aims To investigate trends surgeries, hospitalisations and medication IBD a multinational, population‐based cohort Methods We included 42,894 ulcerative colitis (UC) 24,864 Crohn's (CD) who were diagnosed between 2010 2017 Denmark, Norway Sweden. extracted medications from national registries compared across countries diagnosis...
Studies on early surgery among Crohn's disease patients are few and focus ileocolonic resections.The aim of this nationwide cohort study was to investigate the course in all who underwent late major abdominal surgery.In a Danish from 1997 2015 we included 493 (group 1) resected within 29 days, 472 2) between 30 180 1,518 3) after days diagnosis. Re-operation, hospitalisations medications were analysed.The cumulative risk re-operation lower group 1 (five-year risk: 16.5% vs. 2: 18.2% 3:...
Inflammatory bowel diseases (IBDs) are chronic of unknown cause characterised by a progressive and unpredictable disease course. In the last decade, biological treatment has become cornerstone in IBD. However, one-in-three-to-four patients do not respond to first-line agents another third see their response diminish over time. This highlights an unmet need for optimising use biologicals prediction response. Considering multifaceted nature IBD, we hypothesise that multiomics profiling...
Abstract Background Treatment failure with biological agents is common in patients ulcerative colitis (UC), but the impact of baseline histological disease activity unknown. We aimed to investigate predictive role histopathological findings for treatment UC patients. Methods This a sub-study Danish IBD Biobank Project. Adult bio-naïve (n=129) were followed prospectively while undergoing treatment. Histological was assessed using Nancy Index and Geboes score intestinal biopsies sampled before...
Abstract Background Biological treatment failure is common in patients with ulcerative colitis (UC), but the predictive value of baseline histological activity unknown. Aims We aimed to investigate associations between and outcomes after biological UC. Methods Adult biological-naïve UC (n = 150) were followed prospectively during treatment. Histological was assessed using Nancy Index Geboes score. Endoscopic Mayo Subscore (MES). Associations multivariable models. histological, endoscopic,...
Existing findings on outcomes of anti-tumor-necrosis-factor (TNF) therapy in patients with inflammatory bowel diseases (IBD) are largely based retrospective studies. We aimed to investigate real-world anti-TNF and predictors thereof a prospective IBD cohort.
Abstract Background Biological therapy has been suggested to decrease surgery and hospitalisation risk in patients diagnosed with inflammatory bowel disease (IBD). During 2010 2016, the use of biologics Denmark (DEN), Sweden (SWE) Norway (NOR) increased dramatically time first biologic treatment declined.1 However, impact increasing on outcomes remains be shown real-life practice. In this nationwide study three Nordic countries, we aimed investigate trends rates IBD biological era.1 Høivik...
Background: Patients with Crohn’s disease (CD) are at increased risk of co-occurring immune-mediated inflammatory diseases (IMIDs). As discrepancy exists regarding the phenotypic presentation CD among patients such IMIDs, we aimed to conduct a systematic review meta-analysis characterizing phenotype this subgroup patients. Methods: PubMed, Embase, and Scopus were searched from their earliest records October 2019 for studies reporting behavior localization according Vienna or Montreal...
Abstract Background The use and cost of biological treatment in patients with inflammatory bowel diseases (IBD) continue to rise. Meanwhile, rates primary non-response (PNR) loss response (LOR) are high. We aimed investigate predictors PNR LOR a real-world cohort bio-naïve IBD patients. Methods This study included, 488 adult (52% UC, 47% CD, 1% IBDU) who initiated completed induction therapy drug from May, 2019 – Oct, 2021 at five university hospitals covering, 2.1 M inhabitants. Clinical...